Varicose ulcer
Drug research and approvals for varicose ulcer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 44 studies of varicose ulcer are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 44
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Vacuum Compression Therapy and Tissue Oxygenation in Chronic Leg UlcersNCT07901517 · Not applicable · BTL Industries Ltd. · starts Oct 15, 2026
- Dose-Response Structured Calf Muscle Pump Activation Strategies Versus Unsupervised Home WalksNCT07763782 · Not applicable · MTI University · starts Oct 1, 2026
- Outcomes of Iliac Vein Stenting With Dedicated Venous Stents in Treatment of Chronic Post-thrombotic Venous UlcersNCT07762222 · Not applicable · Ain Shams University · starts Mar 2, 2025
- Noninvasive Artificial Venous Stasis for Reperfusion in STEMINCT07689591 · Not reported · Firat University · starts Aug 15, 2026
- PAW-Hydrogel for Chronic Wound HealingNCT07541196 · Not applicable · Benjamín Gonzalo Rodríguez Méndez · starts Apr 20, 2026
- The GORE® VIABAHN® FORTEGRA Venous Stent Post-Approval StudyNCT07538609 · Not applicable · W.L.Gore & Associates · starts Aug 25, 2026
- Efficacy of Human Placental Membrane Products and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers…NCT07364630 · Not applicable · BioLab Holdings · starts Jan 2, 2026
- ConvaVAC™ Ag+ Negative Pressure Wound Therapy System in Chronic WoundsNCT07342049 · Not applicable · ConvaTec Inc. · starts Jan 12, 2026
- Evaluation of the Efficacy of Hyalomatrix® in the Healing of Chronic Venous Leg UlcersNCT07335861 · Not applicable · NuScience Medical Biologics, LLC · starts May 14, 2026
Approved 2
- Zinc oxideSunscreen/skin protectant
- Glycerin
Phase 2 5
- Nitric oxideSoluble guanylate cyclase activator
- TimololBeta-1 adrenergic receptor antagonist
- RegramostimGranulocyte colony stimulating factor receptor agonist
- Stem bromelainRemoval of necrotic tissue
- Thymosin
Phase 1 or earlier 1
How its trials ended
341 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 79 whose ending is known, 19% met their primary endpoint, 5% missed it and 76% stopped early.
- Completed, result not reported14041%
- Ongoing6820%
- Status unknown5416%
- Stopped: other or unclear288%
- Stopped: enrollment or feasibility185%
- Met its primary endpoint154%
- Stopped: sponsor or business decision72%
- Stopped: lack of efficacy51%
- Missed its primary endpoint41%
- Stopped: funding21%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA